Sutro, Celgene collaborate on R&D of antibody drugs

12/19/2012 | Genetic Engineering & Biotechnology News

Sutro Biopharma agreed to design and develop new antibody-drug conjugates and bispecific antibodies against two undisclosed targets for Celgene using its cell-free protein synthesis technology. The deal also covers the production of a proprietary Celgene antibody. In return, Celgene will give Sutro an upfront payment and as much as $500 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD